ENGN

Business Context and Reporting Period

Company: enGene Holdings Inc. (ENGN)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Quarter and six months ended April 30, 2025
Business Overview: enGene is a clinical-stage biotechnology company developing non-viral genetic medicines for bladder cancer. Its lead product candidate, detalimogene voraplasmid (detalimogene), is in a Phase 1/2 open-label study (LEGEND) for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). The company has no commercial products and has not generated revenue.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased R&D Spend: R&D expenses increased by $24.7 million (159%) for the six months ended April 30, 2025, compared to the prior year period. This was driven by a $19.3 million increase in direct costs for detalimogene (manufacturing and clinical activities for the LEGEND study) and a $4.5 million increase in personnel costs.
• G&A Fluctuation: G&A expenses increased by $1.0 million for the six-month period but decreased by $0.5 million for the three-month period compared to the prior year. The six-month increase was due to higher personnel costs, partially offset by lower professional and legal fees.
• Interest Income: Interest income increased by $1.2 million for the six-month period due to larger cash and marketable securities balances.
• Cash Position: Cash and cash equivalents decreased from $173.0 million at October 31, 2024, to $57.5 million at April 30, 2025, while marketable securities increased significantly, resulting in a total liquid asset position of $251.5 million.

Guidance, Outlook, and Risks

• Outlook: Management expects to continue incurring significant operating losses. The company plans to file a Biologics License Application (BLA) with the FDA in mid-2026 for detalimogene.
• Liquidity: As of April 30, 2025, the company has $251.5 million in cash, cash equivalents, and marketable securities. Management believes this is sufficient to fund operations and debt obligations for at least the next 12 months.
• Debt Facility: The company has a term loan facility with Hercules Capital. $22.5 million has been drawn, with an additional $27.5 million available subject to conditions. The effective interest rate was 11.63% as of April 30, 2025.
• Internal Controls: The company disclosed three unremediated material weaknesses in internal control over financial reporting as of April 30, 2025, including lack of formal policies, IT control deficiencies, and segregation of duties issues. Consequently, disclosure controls and procedures were deemed ineffective.
• Risks: Key risks include the uncertainty of clinical trial outcomes, the ability to raise additional capital, regulatory approval delays, and the company's dependence on the success of detalimogene.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $251.5 million liquid asset position against the projected burn rate, considering the significant increase in R&D spend.
• Debt Covenants: Review the terms of the Hercules Capital term loan, specifically the conditions required to draw the remaining $27.5 million and the impact of the 11.63% effective interest rate.
• Internal Controls: Assess the remediation plan for the three material weaknesses in internal controls and the potential impact on future financial reporting reliability.
• Clinical Progress: Monitor enrollment and data readouts from the LEGEND Phase 2 study, which is critical for the planned mid-2026 BLA submission.
• Subsequent Events: Note the new lease agreement for 26,335 sq. ft. of office space in Boston (effective June 4, 2025) with $10.5 million in base rental payments, which may impact future cash flow.